HomeClinical TopicsFDA approves new daily treatment for RLS

FDA approves new daily treatment for RLS

The U.S. Food and Drug Administration has approved Horizant Extended Release Tablets (gabapentin enacarbil) as a daily treatment for moderate-to-severe restless legs syndrome (RLS). Read more at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm250188.htm.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content

For Nurse Practitioners

Couple talking to NP

Getting Covid Vaccine Won’t Hurt Pregnancy Chances; Getting Covid Could

Couples planning a pregnancy might be relieved to know that getting a Covid vaccine does not hurt their odds of conceiving, according to the...